Przegląd Dermatologiczny

Abstract

4/2026 vol. 113
Original article

Locoregional relapse after excision of cutaneous melanoma

  1. Department of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey

  2. Department of Medical Oncology, Prof. Dr. Cemil Tascioglu Teaching Hospital, University of Health Sciences, Istanbul, Turkey

Dermatol Rev/Przegl Dermatol 2026, 113, 198–203

Online publish date: 2026/11/16
View full text

Introduction

Nearly one-third of patients with resected melanoma experience disease progression in the form of recurrence or metastasis.

Objective

This study aimed to investigate the clinical characteristics of patients with resected non-metastatic cutaneous melanoma who developed locoregional relapses and to compare them with patients who developed distant metastases.

Material and methods

A total of 457 patients with non-metastatic melanoma at presentation resected at stage I–III of cutaneous melanoma who experienced disease progression during or after adjuvant treatment or during follow-up were included in the analysis.

Results

A total of 229 (50.1%) melanoma patients had locoregional relapse alone, whereas distant organ metastases were detected in 228 (49.9%) patients, including 115 (25.2%) with concomitant locoregional recurrence and 113 (24.7%) with distant organ metastases only. Locoregional relapse alone was more common in patients with melanomas located on the limbs (48.7% vs. 38.8%, p = 0.03) and was significantly associated with acral lentiginous melanoma (19.6% vs. 10.7%, p = 0.02) and lymph node-negative disease (56.8% vs. 45.6%, p = 0.01). Patients with locoregional relapse alone had longer survival than those with distant metastases (median survival: 19.5 months vs. 6.5 months, p < 0.001).

Conclusions

Routine skin surveillance and clinical examination are crucial for the early detection of locoregional recurrence. Locoregional involvement was observed in approximately three-quarters of disease progressions among patients initially diagnosed with stage I–III melanoma.

Share
without publication fees
without publication fees